Companies /Healthcare

Illumina Inc

NASDAQ: ILMN Diagnostics & Research
$216.31
▲ $3.06 (+1.43%) today
Markets open · 1:13pm ET
Today · % change

24/7 Wall St. View

Fundamentals

Market Cap
$32.2B
P/E Ratio
38.6
Profit Margin
18.3%
Revenue (TTM)
$4.5B
EPS (TTM)
$5.52
52-Week Range
$88 – $232
Street Target
$198.89

About Illumina

Illumina Inc is a global leader in genomics, offering advanced solutions for DNA sequencing and analysis. Based in San Diego, California, since 1998, Illumina provides a wide range of products, including sequencing and array-based instruments, consumables, and whole-genome sequencing kits. These products cater to genomic research centers, academic institutions, hospitals, and various companies in the biotech and pharmaceutical sectors. Illumina is also pioneering in cancer diagnostics with its multi-cancer early detection test, Galleri, and is developing new technologies for blood-based disease detection and monitoring.

ILMN Coverage

12:00pm ET
Investing

2 Spinoff Stocks Down 16%. Should You Buy Now?

Stock spinoffs are a popular corporate strategy for unlocking shareholder value, but one that rarely pays off for investors. Harvard Business Review found half of all spinoffs failed to create any new…

Rich Duprey